Outlook Therapeutics, Inc.

For fiscal Q3 2026, Outlook reported adjusted net loss attributable to common stockholders of $10.9 million, or $0.09 per basic and diluted share, versus $15.8 million, or $0.44 per share, in fiscal Q3 2025. Management said the adjusted results exclude noncash and nonrecurring items, mainly changes in warrant and promissory note fair value and a debt extinguishment loss. As of June 30, cash and cash equivalents were $11.2 million. After quarter end, the company announced a $55 million common stock and warrant offering, with expected net proceeds of about $51.1 million, intended to fund the U.S. launch and general corporate purposes. Forward guidance called for first 12 months of U.S. launch net revenue of $50 million to $75 million, with Europe contributing 10% to 15% of that total; about 10% of first-year revenue is expected in the first 3 months and about 50% in the fourth quarter after launch. SG&A is expected to approximately double by the end of calendar 2026 and rise another 10% in calendar 2027, while R&D should remain relatively steady over the next 12 months.

Bob Jahr framed the FDA approval as transformational and said the company is now focused on converting that regulatory win into a disciplined commercial launch. He emphasized that LYTENAVA is aimed at the established repackaged bevacizumab market, not the branded anti-VEGF category, and argued that the product combines bevacizumab familiarity with FDA manufacturing and quality standards. His tone was confident but measured: he repeatedly described the launch plan as conservative, market-tested, and dependent on execution, access, and reimbursement.

Lawrence Kenyon highlighted the quarter’s adjusted net loss of $10.9 million, or $0.09 per share, and noted that cash was $11.2 million at June 30 before the subsequent financing. He said the $55 million offering, expected to yield about $51.1 million net, is meant to support the U.S. commercial launch and working capital needs. On operating expense, he guided SG&A to roughly double by the end of 2026 and then increase another 10% in 2027, while R&D should stay relatively steady as the prefilled syringe program advances.

Analysts focused on how much upside exists if compounded repackaged bevacizumab becomes less available, how LYTENAVA compares with biosimilars on pricing and access, and how patient out-of-pocket costs could affect adoption without the Good Days Foundation support. Management said disruption in the compounded market could add just under $300 million of upside to the $500 million 2030 base case, but not all of that would necessarily flow to LYTENAVA because some could go to biosimilars. Bob Jahr also said many Medicare and Medicare Advantage plans still require step therapy, that the company’s pricing work aims to keep out-of-pocket burdens manageable, and that early adopters appear to be a meaningful slice of retina physicians who already rely heavily on compounded bevacizumab.